|
|
|
| Influence of sequential DC-CIK cell therapy on survival rate and immune function after local advanced non-small cell lung cancer surgery |
| AI Yueqin1 JIANG Longwei2▲ ZHAO Hua2 GAO Yanrong2 JIA Shaochang2 |
1.Department of Respiration, Bayi Hospital Affiliated Nanjing University of Chinese Medicine, Jiangsu Province, Nanjing 210002, China;
2.Department of Biotherapy, Bayi Hospital Affiliated Nanjing University of Chinese Medicine, Jiangsu Province, Nanjing 210002, China |
|
|
|
Abstract Objective To investigate the influence of Dendritic cell (DC) and Cytokine-induced killer (CIK) cell therapy on the survival rate and immune function of local non-small cell lung cancer. Methods From January 2014 to January 2017, in Bayi Hospital Affiliated Nanjing University of Chinese Medicine, 40 NSCLC patients were selected, they were divided into treatment group (22 cases) and control group (18 cases) by random sampling table method. The control group was treated with adjuvant chemotherapy alone, and the treatment group was treated with DC, CIK combined with chemotherapy. The postoperative survival rate, serum tumor markers, immune function, and adverse reactions of patients in two groups were compared. Results The median survival time of the treatment group was compared with the control group, the difference was not statistically significant (P > 0.05), but the disease-free survival time of the treatment group was higher than the control group, the difference was statistically significant (P < 0.05). After treatment, serum tumor markers CEA and CYFRA21-1 in two groups were compared, the difference was not statistically significant (P > 0.05). After treatment, the ratio of helper T cells and CD4+/CD8+ T cells in the treatment group were significantly higher than the control group, the differences were statistically significant (P < 0.05), and the rDNA transcription activity of T lymphocytes in the treated group was significantly higher than the control group, the difference was statistically significant (P < 0.05). There was no significant difference in chemotherapy-related adverse effects between the two groups, in the treatment group, 3 patients with DC and CIK treatment had related fever reactions. Conclusion Sequential use of DC-CIK cells in patients with locally advanced non-small cell lung cancer can lead to clinical benefit of disease-free survival and enhanced immune function. It is a safe and effective treatment and worthy of clinical promotion and application.
|
|
|
|
|
|
[1] Torre LA，Bray F，Siegel RL，et al. Global Cancer Statistics，2012 [J]. Ca A Cancer J Clin，2015，65（2）：87-108.
[2] Black RC，Khurshid H. NSCLC： an update of driver mutations，their role in pathogenesis and clinical significance [J]. Rhode Island Med J，2015，98（10）：25-28.
[3] Anguille S，Smits EL，Lion E，et al. Clinical use of dendritic cells for cancer therapy [J]. Lancet Oncol，2014，15（7）：e257-e267.
[4] Steinman RM. Decisions about dendritic cells：past，present，and future [J]. Annu Rev Immunol，2012，30（1）：1-22.
[5] Niam M，Linn YC，Chong SF，et al. Clinical scale expansion of cytokine-induced killer cells is feasible from healthy donors and patients with acute and chronic myeloid leukemia at various stages of therapy [J]. Exp Hematol，2011，39（9）： 897-903.
[6] Fl?觟rcken A，Kopp J，Lessen AV，et al. Allogeneic partially HLA-matched dendritic cells pulsed with autologous tumor cell lysate as a vaccine in metastatic renal cell cancer： a clinical phase Ⅰ/Ⅱ study [J]. Hum Vaccines，2013， 9（6）：1217-1227.
[7] Um SJ，Choi YJ，Shin HJ，et al. Phase I study of autologous dendritic cell tumor vaccine in patients with non-small cell lung cancer [J]. Lung Cancer，2010，70（2）：188-194.
[8] de Rosa F，Ridolfi L，Ridolfi R，et al. Vaccination with autologous dendritic cells loaded with autologous tumor lysate or homogenate combined with immunomodulating radiotherapy and/or preleukapheresis IFN-α in patients with metastatic melanoma：a randomised “proof-of-principle” phase Ⅱ study [J]. J Transl Med，2014，12：209.
[9] de Kock I，Mirhosseini M，Lau F，et al. Conversion of karnofsky performance status （KPS） and eastern cooperative oncology group performance status （ECOG） to palliative performance scale （PPS），and the interchangeability of PPS and KPS in prognostic tools [J]. J Palliat Care，2013，29（3）：163-169.
[10] 江龙委，黄伟谦，姚露，等.DC疫苗联合CIK细胞治疗39例中晚期宫颈癌的临床疗效观察及预后分析[J].中国肿瘤生物治疗杂志，2015，22（6）：765-772.
[11] Reck M，Rabe KF. Precision diagnosis and treatment for advanced non-small-cell lung cancer [J]. N Engl J Med，2017，31：377（9）：849-861.
[12] 刘鹏辉，廖国清，李亮亮，等.DC-CIK细胞对非小细胞肺癌术后患者的生存率及免疫功能的影响[J].中国医刊，2012，47（11）：32-35.
[13] 朱婷，江蓓蕾，江茜，等.自体CIK细胞治疗对中晚期非小细胞肺癌患者免疫功能及生活质量的影响[J].中国肿瘤生物治疗杂志，2015，22（1）：84-88.
[14] Jangani M，Poolman TM，Matthews L，et al. The methyltransfe rase WBSCR22/Merml enhances glucocorticoid receptor fun ction and is regulated in lung inflammation and cancer [J]. J Biol Chem，2014，289（13）：8931-8946.
[15] 周松林，徐文波.胸腔镜下手术对肺癌患者血流动力学及免疫功能的影响[J].中国内镜杂志，2015，21（4）：344-347.
[16] 唐兴，何靖康，马海涛.全胸腔镜与开胸肺叶切除术对患者围手术期免疫功能的影响[J].江苏医药，2013，39（9）：1062-1064.
[17] 赵华，艾月琴，郑劼，等.广泛期小细胞肺癌放化疗联合细胞免疫治疗的效果[J].中国医药导报，2016，13（2）：104-108.
[18] 肖梅，艾月琴，张闯，等.CIK细胞联合紫杉醇治疗上皮性卵巢癌的初步研究[J].中国医学创新，2014，11（33）：150-153.
[19] 郑劼，江龙委，姚露，等.DC-CIK细胞治疗晚期结直肠癌的临床疗效[J].中国肿瘤生物治疗杂志，2015，22（4）：459-464.
[20] 姚露，张燕，黄伟谦，等.DC-CIK免疫细胞治疗晚期乳腺癌患者的临床疗效[J].中国肿瘤生物治疗杂志，2016， 23（4）：519-524. |
|
|
|
